ClinicalTrials.gg

Depression clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 8,601 studies for Depression across more than 10 countries. 1,735 are recruiting or about to start. 4,349 of them are mainly about Depression (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 12,984 studies for Depression. How that becomes 8,590 here

This page counts the studies the registry files under Depression, and those it files under no condition that list Depressionthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 12,984Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,555List Depression as a condition, but the registry did not file them under itMost often written as “Postpartum Depression” (208), “Major Depression” (208), and “Treatment Resistant Depression” (160). The registry filed 10 of them under no condition at all, and the others under other conditions only, most often Depression, Postpartum (421) and Depressive Disorder, Major (363).
  3. −2,842Match it another way1,267 name it in the title, 210 in a keyword, and 1,365 by a synonym or other text the search reads.
  4. 8,587Counted here and found by its search320 of them list Depression in their own words; the registry filed them under no condition.
  5. +3
    Counted here, but its search does not find them
  6. 8,590The count on this page

Status

Completed
5,132
Recruiting
1,097
Status unknown
812
Not yet recruiting
514
Terminated
378
Active, not recruiting
301

Phase

Phase 2
691
Phase 3
471
Phase 4
455
Phase 1
322
Early Phase 1
75

Where

United States
3,715
Canada
533
China
358
Turkey
342
United Kingdom
283
Germany
268

Who develops what

Add Depression to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 22 programs from 20 companies, 6 with this as their studies’ main aim; 8 with a live phase 3 study; 14 primary completions in the next 12 months. Compare China Resources Pharmaceutical Group, Bristol-Myers Squibb and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BupropionRecent, limited
Evidence
  • NCT06223880 · Axsome Therapeutics, Inc. · Phase 4 · live · comparator · “Bupropion” · registered Jan 2024
  • NCT03595579 · Axsome Therapeutics, Inc. · Phase 2 · comparator · “Bupropion” · registered Jun 2018
  • NCT02741791 · Axsome Therapeutics, Inc. · Phase 3 · comparator · “Bupropion” · registered Apr 2016
GlaxoSmithKline28% of its industry studiesUS: off-patent, 31 generics marketed11 study
EscitalopramEarlier only
Evidence
  • NCT01369095 · Bristol-Myers Squibb · Phase 2 · comparator · “Escitalopram” · registered Jun 2011
  • NCT01364649 · Takeda · Phase 3 · comparator · “Escitalopram” · registered May 2011
  • NCT01360866 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Escitalopram” · registered May 2011
  • NCT01020799 · AstraZeneca · Phase 2 · comparator · “Escitalopram” · registered Nov 2009
  • NCT00822744 · Sanofi · Phase 2 · comparator · “Escitalopram” · registered Jan 2009
AbbVie19% of its industry studiesUS: off-patent, 16 generics marketed00 studies
duloxetineEarlier only
Evidence
  • NCT01369095 · Bristol-Myers Squibb · Phase 2 · comparator · “Duloxetine” · registered Jun 2011
  • NCT01360866 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Duloxetine” · registered May 2011
  • NCT01309945 · Bristol-Myers Squibb · Phase 2 · comparator · “Duloxetine” · registered Feb 2011
  • NCT01153009 · Takeda · Phase 3 · comparator · “Duloxetine” · registered Jun 2010
  • NCT01145755 · AstraZeneca · Phase 2 · comparator · “Duloxetine” · registered May 2010
Eli Lilly and Company84% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized00 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
JS1-1-01 low-dose group☆ Track1 live phase-3 study: NCT07485595China Resources Pharmaceutical Group Limited
JS1-1-01 high-dose group☆ Track1 live phase-3 study: NCT07485595China Resources Pharmaceutical Group Limited

The 2 in phase 3 with the nearest primary completion, of 22 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (14)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.JS1-1-01 low-dose group, JS1-1-01 high-dose group · China Resources Pharmaceutical Group Limited · Phase 3 main aimNCT07485595 A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression — primary endpoint: The change in MADRS total score from baseline · 180 enrolled
  • Jan 2027 est.azetukalner · Xenon Pharmaceuticals Inc. · Phase 3 registry mapping onlyNCT06922110 An Open-Label Study of Azetukalner in Major Depressive Disorder — primary endpoint: Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest · 460 enrolled
  • Mar 2027 est.SPT-300 · Seaport Therapeutics · Phase 2 registry mapping onlyNCT07065240 A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — primary endpoint: Change From Baseline to Day 42 in Hamilton Depression Rating Scale-17 (HAM-D-17) Total Score · 360 enrolled

11 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Depression studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Serotonin receptor agonists 31 open · Psychedelics 27 open · SSRIs 19 open · SNRIs 5 open · Antipsychotics 4 open

Coming up

656studies finish main data collection within a year14 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 1,097 Depression studies recruiting now, 473 (43%) set no upper age limit and 523 (48%) stop at 75 or younger. 206 (19%) take children under 18. 98 (9%) are for women only and 3 (<1%) for men only; 314 (29%) take healthy volunteers.

Recruiting studies that take each age, of 1,097
AgeWomenMen
1076 (7%)71 (6%)
18850 (77%)774 (71%)
30826 (75%)749 (68%)
40838 (76%)756 (69%)
50836 (76%)764 (70%)
65801 (73%)746 (68%)
75606 (55%)557 (51%)
85532 (48%)484 (44%)

Across all 8,601 studies, recruiting or not: 48% stop at 75 or younger and 40% at 65; 17% take children; 11% are for women only and 1% for men only; 30% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Depression studies take

Of 197 phase 2 interventional studies under Depression, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 127 mo11–54 · 102 studies—33 mo16–61 · 82 studies
Phase 1/234 mo12–59 · 42 studies——
Phase 231 mo18–47 · 197 studies17 mo12–29 · 53 studies38 mo27–57 · 144 studies
Phase 2/340 mo27–56 · 32 studies—49 mo28–56 · 30 studies
Phase 328 mo21–44 · 81 studies—28 mo22–44 · 55 studies
Phase 432 mo17–59 · 119 studies—34 mo17–59 · 110 studies
Interventional, no phase21 mo9–41 · 3,580 studies9 mo5–18 · 98 studies21 mo10–41 · 3,482 studies
Observational32 mo13–62 · 495 studies25 mo12–42 · 33 studies33 mo14–63 · 462 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting23

Show 18 more

Newly registered74

Show 45 more

and 24 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 8,601. Browse all 8,601 → or search them.